Status epilepticus is a condition that is characterized by repeated seizures and is a medical emergency. Treatment is usually with a Benzodiazepine such as Diazepam or Lorazepam etc. There have been ...
TORONTO, Nov. 24, 2021 (GLOBE NEWSWIRE) -- PharmaTher Holdings Ltd. (the “Company” or “PharmaTher”) (OTCQB: PHRRF) (CSE: PHRM), a clinical-stage psychedelics biotech company, is pleased to announce ...
Please provide your email address to receive an email when new articles are posted on . The FDA granted orphan drug designation to PharmaTher for its status epilepticus ketamine treatment, according ...
Drexel University College of Medicine researchers are conducting an emergency medicine study to find out the most effective drug for treating established status epilepticus -- a life-threatening ...
When it comes to seizure treatment, timing is key. Now, armed with a nod for an easily storable version of the status epilepticus drug fosphenytoin, Sedor Pharmaceuticals aims to get the potentially ...
University of Virginia Brain Institute and School of Medicine researchers have received an initial $9.3 million award from the National Institutes of Health to determine if the powerful anesthetic ...
Credit: Shutterstock. The product is a ready-to-dilute, room temperature stable formulation of fosphenytoin for IV injection, which allows for point-of-care storage. The Food and Drug Administration ...
PharmaTher, a Toronto-based biotechnology company focused on discovering and developing drugs using Ketamine, received an Orphan Drug Designation (ODD) for a ketamine-based medicine to treat a rare ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback